Theranica Ltd.

23 articles about Theranica Ltd.

• Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in India

  1/10/2023

  Theranica announced a strategic license and supply agreement with Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, for the exclusive marketing and distribution of FDA-approved Nerivio® in India, subject to completion of the regulatory approval process in India.

• Point32Health to Pilot Nerivio® Drug-Free Migraine Treatment Device

  10/24/2022

  Theranica announced today it has teamed up with Point32Health, the parent organization of Harvard Pilgrim Health Care and Tufts Health Plan, to conduct a 12-month pilot aimed at treating the organization's commercial members suffering from episodic and chronic migraine.

• Theranica Secures $45 Million Series C Funding Round

  8/29/2022

  Theranica today announced the closing of its Series C funding round, with a first closing of $45 million.

• MC-Rx Formalizes Pharmacy Benefit Coverage for Theranica's Nerivio®, Providing Millions of Covered Members Access to the Novel Drug-Free Migraine Therapeutic

  10/4/2021

  Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced it has signed an agreement with pharmacy benefit manager MC-Rx, which places Theranica's flagship Nerivio® device for acute treatment of migraine under MC-Rx's Pharmacy Benefit formulary.

• Nerivio® Wins 2021 Medical Design Excellence Award

  6/1/2021

  The First Smartphone-Controlled, Prescription Wearable Device for the Acute Treatment of Migraine, Nerivio, Wins Silver at MDEA

• Nerivio® Wins 2021 MedTech Breakthrough Award

  5/6/2021

  Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced that its Nerivio® therapeutic wearable has been selected as the winner of the "Best New Technology Solution for Pain Management" award in the fifth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough.

• FDA Approves Theranica's Nerivio® for Acute Treatment of Migraine in Adolescents

  1/25/2021

  Theranica , a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced that its Nerivio ® therapeutic device has has received the Food and Drug Administration clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older.

• Theranica Adds Digital Therapeutics Expert Donald Jones to its Board of Directors

  1/19/2021

  Theranica , a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced the addition of Donald Jones to its board of directors.

• Theranica Reports Positive Study Results of Nerivio® for Adolescent Migraine Patients

  12/22/2020

  New Peer-reviewed Article Publishes Results of Clinical Study Testing Safety and Efficacy of Remote Electrical Neuromodulation for Acute Treatment of Migraine in Patients Aged 12-17

• Nerivio® Smartphone-Controlled Wearable for Acute Treatment of Migraine Granted CE Mark for Use in Europe

  9/8/2020

  Theranica Announces Nerivio will be Available in Select European Countries Starting in 2021

• Theranica Reports Positive Study Results of Nerivio® for Chronic Migraine Patients

  7/15/2020

  Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that a new peer-reviewed study  demonstrates the utility of incorporating Remote Electrical Neuromodulation (REN) into usual care of chronic migraine.

• Theranica Kicks Off Migraine Awareness Month Rebate Program for Nerivio®, Its FDA-Authorized Migraine Treatment Wearable

  6/1/2020

  Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced its Migraine Awareness Month $50 rebate for new Nerivio® prescriptions dispensed during June 2020.

• Theranica Expands Executive Team Amid Growing US Demand for Its FDA-authorized Migraine Treatment Wearable Device

  5/18/2020

  Theranica today announced the appointment of two senior executives amid growing demand for the company's prescription migraine treatment device Nerivio®.

• Theranica Named to Fast Company's Annual List of the World's Most Innovative Companies for 2020

  3/10/2020

  Developer of Nerivio™, a Drug-Free Therapeutic Wearable for the Acute Treatment of Migraine,

• Theranica Named 2020 'Game Changer' by CB Insights

  12/18/2019

  BioMed Tech Developer Included in "Electro-Charged Therapeutics" Category Recognizing Companies Creating a Drug-Free Future

• Theranica Announces U.S. Recycling Partnership in Commitment to Sustainable Medical Device Production

  11/18/2019

  Partnership Advances Circular Economy by Making Nerivio™, a Prescribed Wearable for Acute Treatment of Migraine, Recyclable

• Theranica: New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications

  7/23/2019

   Theranica, a bio-medical technology company developing advanced electroceuticals for migraine and other pain disorders, announced today the publication of a peer-reviewed paper demonstrating that Remote Electrical Neuromodulation (REN) is as effective as acute pharmacological treatments in treating the symptoms of migraine.

• FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device

  5/28/2019

  Clinical Data Show 66.7% Pain Relief Response Within Two Hours

• OMRON VENTURES Joins Theranica's Series B Funding Round as Strategic Investor

  5/13/2019

  Strategic investment signals positive response of healthcare community to Theranica's new approach to migraine management

• Theranica Raises $35M to Bring Innovative Migraine Device to the USA

  3/18/2019

  aMoon leads round B of financing of the Israel-based company